Aarvik Therapeutics advances ARR-002 into Phase 1 and licenses two ADC candidates to Laurus Labs for India
Aarvik Therapeutics has reached its first human clinical milestone through ArriVent Biopharma's ARR-002 study and signed a separate India-focused licensing agreement with Laurus Labs. The developments extend its antibody-drug conjugate platform commercially, but clinical efficacy and the value of the new licensing arrangement remain undisclosed.